Aspartyl protease inhibitors
Patent 5883252 Issued on March 16, 1999. Estimated Expiration Date: 
January 26, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
January 26, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3882120 N(Sulfonyl)anilines for treating angina pectoris Sulphoxides Amino acid ester and amide renin inhibitors Amino acid derivatives Aminated alkoxylated imidazolidones Retroviral protease inhibiting compounds HIV protease inhibitors useful for the treatment of AIDS Imidazolidone polyetheramide surfactant Patent #: 5436351 Inventors
AssigneeApplicationNo. 592777 filed on 01/26/1996US Classes:544/71, Spiro oxazine544/231, Spiro diazine544/336, 1,4-diazines544/384, Chalcogen bonded directly to piperazine ring carbon548/127, 1,2,3-thiadiazoles (including hydrogenated)548/206, 1,2-thiazoles (including hydrogenated)548/311.1, Additional hetero ring attached directly or indirectly to the diazole ring by nonionic bonding (e.g., 1,3-dioxolan-2-yl methyl-imidazole, etc.)548/323.5, Chalcogen attached indirectly to the diazole ring by acyclic nonionic bonding548/324.1, The chalcogen, X, is in a -C(=X)- group548/550Nitrogen attached directly or indirectly to the five-membered hetero ring by acyclic nonionic bondingExaminersPrimary: Higel, Floyd D.Attorney, Agent or FirmForeign Patent References
International ClassesC07D 307/20C07D 319/06 C07D 493/04 C07D 211/60 C07D 241/04 C07D 277/06 AbstractThis invention relates to a novel class of compounds that are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting aspartyl protease activity and methods for treating viral infections using the compounds and compositions of this invention.Other References
Field of SearchChalcogen attached indirectly to the diazole ring by acyclic nonionic bondingThe chalcogen, X, is in a -C(=X)- group 1,2,3-thiadiazoles (including hydrogenated) 1,2-thiazoles (including hydrogenated) Additional hetero ring attached directly or indirectly to the diazole ring by nonionic bonding (e.g., 1,3-dioxolan-2-yl methyl-imidazole, etc.) Nitrogen attached directly or indirectly to the five-membered hetero ring by acyclic nonionic bonding Chalcogen or nitrogen bonded directly to the imidazole ring by nonionic bonding Spiro or additional polycyclo ring system Plural ring nitrogens and a single chalcogen in the hetero ring 1,2-thiazoles (including hydrogenated) Additional hetero ring Chalcogen bonded directly to the five-membered hetero ring by nonionic bonding Spiro oxazine Spiro diazine 1,4-diazines Chalcogen bonded directly to piperazine ring carbon |
| ||||||||||||||
